Sunesis Pharmaceuticals Inc.
395 Oyster Point Boulevard
Suite 400
South San Francisco,
CA 94080
United States - Map
Phone: 650-266-3500
Fax: 650-266-3505
Web Site: http://www.sunesis-pharma.com
| Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumor cancers. Its primary product candidate is Voreloxin, an anticancer quinolone derivative (AQD) for the treatment of cancer in Phase 2 development stage. The company is conducting various clinical trials of Voreloxin, including a Phase 2 clinical trial, known as the REVEAL-1 trial, in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in advanced platinum-resistant ovarian cancer patients. Sunesis Pharmaceuticals has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and marketing of Voreloxin. It was formerly known as Mosaic Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in South San Francisco, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Daniel N. Swisher Jr., 45
Chief Exec. Officer, Pres |
N/A
| N/A | Mr. Eric H. Bjerkholt , 49
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. & Corp. Devel. |
N/A
| N/A | Dr. Steven B. Ketchum Ph.D., 44
Sr. VP of R&D |
N/A
| N/A | Dr. Judith A. Fox Ph.D,
VP of Product & Preclinical Devel. |
N/A
| N/A | Dr. Glenn C. Michelson M.D.,
VP of Clinical Strategy |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.23% Nasdaq 
Profile
